Index RUT
P/E -
EPS (ttm) -2.56
Insider Own 19.19%
Shs Outstand 82.29M
Perf Week 7.42%
Market Cap 321.91M
Forward P/E -
EPS next Y -1.45
Insider Trans 4.14%
Shs Float 78.12M
Perf Month 13.27%
Income -215.99M
PEG -
EPS next Q -0.38
Inst Own 67.51%
Short Float 3.47%
Perf Quarter 25.66%
Sales 66.75M
P/S 4.82
EPS this Y 42.66%
Inst Trans 4.63%
Short Ratio 4.51
Perf Half Y -27.77%
Book/sh -1.36
P/B -
EPS next Y 13.73%
ROA -49.14%
Short Interest 2.71M
Perf Year 333.59%
Cash/sh 3.10
P/C 1.07
EPS next 5Y 15.80%
ROE -705.53%
52W Range 0.36 - 6.04
Perf YTD 100.60%
Dividend Est. -
P/FCF -
EPS past 5Y 84.52%
ROI -
52W High -44.87%
Beta 1.58
Dividend TTM -
Quick Ratio 5.90
Sales past 5Y 91.46%
Gross Margin 92.13%
52W Low 825.24%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 6.17
EPS Y/Y TTM -13.36%
Oper. Margin -207.40%
RSI (14) 62.22
Volatility 6.20% 7.36%
Employees 162
Debt/Eq -
Sales Y/Y TTM -63.80%
Profit Margin -323.60%
Recom 1.43
Target Price 9.80
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 33.96%
Payout -
Rel Volume 3.13
Prev Close 3.21
Sales Surprise -7.81%
EPS Surprise 16.89%
Sales Q/Q -9.71%
Earnings Aug 06 BMO
Avg Volume 601.94K
Price 3.33
SMA20 12.65%
SMA50 5.91%
SMA200 -2.24%
Trades
Volume 1,886,539
Change 3.74%
Date
Action
Analyst
Rating Change
Price Target Change
May-30-24 Initiated
Cantor Fitzgerald
Overweight
Mar-28-24 Initiated
Guggenheim
Buy
$11
Aug-10-23 Upgrade
JP Morgan
Underweight → Neutral
Apr-24-23 Downgrade
BofA Securities
Neutral → Underperform
$7 → $2
Dec-06-22 Initiated
CapitalOne
Overweight
$12
Nov-09-22 Downgrade
BofA Securities
Buy → Neutral
$14 → $7
Sep-21-22 Initiated
JP Morgan
Overweight
$5
Sep-09-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$17 → $11
Nov-09-21 Initiated
Wolfe Research
Outperform
$44
Aug-17-21 Resumed
Jefferies
Buy
$40
Aug-09-21 Initiated
RBC Capital Mkts
Outperform
$33
Jun-15-21 Initiated
Cantor Fitzgerald
Overweight
$13
Dec-03-20 Initiated
Stifel
Hold
$42
Oct-29-20 Initiated
H.C. Wainwright
Buy
$47
Jun-09-20 Initiated
Cowen
Outperform
Jun-09-20 Initiated
BofA/Merrill
Buy
$45
Show Previous Ratings
Sep-03-24 04:05PM
07:15AM
Aug-06-24 08:40AM
07:30AM
Aug-01-24 04:05PM
(GlobeNewswire) -7.83%
-5.88%
07:15AM
Loading…
Jul-30-24 07:15AM
Jul-11-24 03:24PM
Jul-08-24 02:00AM
Jul-01-24 04:05PM
(GlobeNewswire) +16.46%
-5.43%
Jun-27-24 07:15AM
Jun-13-24 02:31PM
Jun-03-24 04:05PM
May-30-24 07:15AM
May-15-24 07:15AM
May-09-24 07:01PM
07:15AM
Loading…
07:15AM
May-07-24 08:55AM
08:44AM
May-06-24 10:53AM
08:22AM
07:30AM
07:20AM
06:55AM
06:10AM
06:00AM
May-01-24 04:05PM
07:00AM
Apr-16-24 08:30AM
Apr-04-24 07:00AM
Apr-03-24 07:00AM
04:05PM
Loading…
Apr-01-24 04:05PM
Mar-15-24 12:30PM
Mar-14-24 05:16AM
(Thomson Reuters StreetEvents)
Mar-13-24 08:51AM
08:20AM
07:00AM
Mar-06-24 07:15AM
07:00AM
Mar-05-24 05:45PM
Feb-27-24 07:00AM
Feb-20-24 10:00AM
Feb-16-24 03:57AM
Feb-15-24 11:57AM
Feb-08-24 01:15PM
Jan-19-24 01:05PM
09:40AM
Jan-04-24 10:05AM
(FierceBiotech.com) +13.25%
07:15AM
07:00AM
Dec-12-23 05:15AM
Nov-20-23 02:40AM
Nov-15-23 03:00AM
Nov-08-23 01:26PM
01:03AM
(Thomson Reuters StreetEvents)
Nov-07-23 08:15AM
07:15AM
07:00AM
Nov-06-23 07:00AM
Nov-02-23 05:50PM
10:10AM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 07:00AM
Oct-04-23 04:00AM
Sep-05-23 07:00AM
Aug-30-23 07:33PM
Aug-14-23 10:51AM
Aug-11-23 10:53AM
Aug-10-23 10:31AM
Aug-09-23 12:09PM
Aug-08-23 11:01PM
(Thomson Reuters StreetEvents) +11.89%
10:48AM
08:15AM
07:00AM
Aug-07-23 05:25PM
Aug-04-23 08:40AM
08:12AM
Aug-03-23 11:48AM
11:45AM
08:02AM
Aug-02-23 12:45PM
12:42PM
Aug-01-23 10:45AM
07:22AM
07:00AM
Jul-28-23 08:02AM
Jul-26-23 08:52AM
Jul-24-23 01:20PM
11:12AM
07:21AM
Jul-21-23 01:22PM
07:44AM
Jul-20-23 04:05PM
Jul-19-23 09:59AM
Jul-18-23 11:04AM
Jul-17-23 10:59AM
10:06AM
Jul-14-23 10:56AM
09:55AM
08:03AM
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Redmile Group, LLC 10% Owner Jul 01 '24 Buy 2.81 400,000 1,124,000 15,669,217 Jul 03 08:00 PM Redmile Group, LLC 10% Owner Jul 01 '24 Buy 2.81 400,000 1,124,000 12,995,040 Jul 03 08:00 PM Azelby Robert Director Jun 17 '24 Sale 2.89 6,995 20,216 53,005 Jun 18 09:45 PM BIZZARI JEAN-PIERRE Director Jun 17 '24 Sale 2.89 6,995 20,216 79,502 Jun 18 09:43 PM Hug Peter Director Jun 17 '24 Sale 2.89 1,193 3,448 182,644 Jun 18 09:41 PM Monges Viviane Director Jun 17 '24 Sale 2.89 1,437 4,153 106,627 Jun 18 09:40 PM Pfisterer Thomas Director Jun 17 '24 Sale 2.89 1,437 4,153 213,900 Jun 18 09:38 PM Sandor Victor Director Jun 17 '24 Sale 2.89 6,995 20,216 80,886 Jun 18 09:37 PM Squarer Ron Director Jun 17 '24 Sale 2.89 6,995 20,216 80,663 Jun 18 09:35 PM MALLIK AMEET Chief Executive Officer May 07 '24 Sale 4.48 29,731 133,195 1,167,348 May 09 04:06 PM
Index RUT
P/E -
EPS (ttm) -0.93
Insider Own 19.41%
Shs Outstand 93.09M
Perf Week 10.77%
Market Cap 490.58M
Forward P/E -
EPS next Y -0.65
Insider Trans -12.40%
Shs Float 91.51M
Perf Month -0.69%
Income -92.26M
PEG -
EPS next Q -0.19
Inst Own 58.43%
Short Float 13.20%
Perf Quarter 43.05%
Sales 3.25M
P/S 150.95
EPS this Y 35.83%
Inst Trans 3.14%
Short Ratio 8.20
Perf Half Y -18.18%
Book/sh 1.95
P/B 2.21
EPS next Y 15.58%
ROA -36.20%
Short Interest 12.08M
Perf Year 184.21%
Cash/sh 1.42
P/C 3.03
EPS next 5Y 23.30%
ROE -42.24%
52W Range 1.11 - 6.72
Perf YTD 2.86%
Dividend Est. -
P/FCF -
EPS past 5Y -46.78%
ROI -40.14%
52W High -35.71%
Beta 2.21
Dividend TTM -
Quick Ratio 6.49
Sales past 5Y 37.94%
Gross Margin -324.52%
52W Low 288.80%
ATR (14) 0.30
Dividend Ex-Date -
Current Ratio 6.49
EPS Y/Y TTM 23.61%
Oper. Margin -3008.03%
RSI (14) 58.11
Volatility 6.51% 7.01%
Employees 156
Debt/Eq 0.06
Sales Y/Y TTM -62.04%
Profit Margin -2838.89%
Recom 1.29
Target Price 8.00
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 51.70%
Payout -
Rel Volume 1.15
Prev Close 4.31
Sales Surprise -33.41%
EPS Surprise -21.28%
Sales Q/Q -62.28%
Earnings Aug 14 AMC
Avg Volume 1.47M
Price 4.32
SMA20 6.04%
SMA50 6.11%
SMA200 1.60%
Trades
Volume 1,691,697
Change 0.23%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-03-24 Initiated
Morgan Stanley
Overweight
$7
Mar-14-24 Initiated
Scotiabank
Sector Outperform
$13
Dec-05-23 Initiated
KeyBanc Capital Markets
Overweight
$3
May-04-23 Initiated
H.C. Wainwright
Buy
$4
Aug-12-22 Downgrade
JP Morgan
Overweight → Underweight
Jul-18-22 Initiated
Truist
Buy
$8
Mar-02-22 Resumed
Cowen
Market Perform
Feb-01-22 Initiated
Berenberg
Buy
$28
Nov-10-21 Downgrade
BofA Securities
Neutral → Underperform
$10
Oct-15-21 Resumed
Cowen
Market Perform
Aug-16-21 Initiated
Stifel
Hold
$28
Aug-16-21 Initiated
Credit Suisse
Outperform
$40
Aug-16-21 Initiated
Cowen
Market Perform
Aug-16-21 Initiated
BofA Securities
Neutral
$26
Show Previous Ratings
Aug-31-24 02:37PM
Aug-30-24 10:30AM
Aug-21-24 08:00AM
Aug-14-24 05:30PM
04:01PM
08:00AM
Loading…
Aug-12-24 08:00AM
Jul-31-24 04:25AM
Jul-10-24 08:00AM
Jul-03-24 04:00PM
Jun-21-24 11:08AM
Jun-12-24 08:00AM
May-28-24 08:00AM
May-20-24 09:32PM
May-16-24 07:15AM
May-15-24 03:01AM
11:53AM
Loading…
May-14-24 11:53AM
07:30AM
May-12-24 03:26PM
May-07-24 09:13AM
Apr-16-24 08:00AM
Apr-10-24 11:07AM
Mar-28-24 04:05PM
Mar-23-24 05:31AM
Mar-21-24 02:52PM
07:30AM
Mar-12-24 05:34PM
Mar-06-24 06:34AM
Mar-01-24 04:01PM
(GlobeNewswire) +5.81%
+5.13%
06:49AM
Feb-27-24 10:20PM
04:01PM
Loading…
04:01PM
Feb-21-24 07:30AM
Feb-20-24 08:00AM
Feb-05-24 09:40AM
Jan-10-24 07:30AM
Jan-08-24 07:00AM
Jan-03-24 08:00AM
Dec-28-23 08:00AM
Dec-20-23 07:30AM
Dec-05-23 08:11AM
Dec-04-23 07:30AM
06:18AM
Dec-03-23 01:27AM
01:22AM
12:21AM
12:00AM
Nov-15-23 08:00AM
Nov-14-23 06:15PM
04:05PM
02:16AM
Oct-26-23 08:00AM
Sep-21-23 08:00AM
Sep-06-23 08:00AM
Aug-28-23 04:05PM
Aug-14-23 03:51PM
08:02AM
08:00AM
Aug-10-23 08:00AM
Aug-01-23 08:00AM
Jul-26-23 08:00AM
Jun-15-23 08:00AM
Jun-07-23 09:32AM
Jun-06-23 08:00AM
May-15-23 05:45PM
04:05PM
May-11-23 08:00AM
May-03-23 10:00AM
Apr-06-23 08:00AM
Apr-04-23 08:00AM
Apr-01-23 08:25AM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Mar-07-23 08:00AM
06:08AM
Feb-28-23 08:00AM
Feb-21-23 08:00AM
Feb-09-23 08:00AM
Feb-08-23 08:00AM
Jan-10-23 10:36AM
10:00AM
(American City Business Journals)
08:00AM
Jan-08-23 03:13PM
Dec-29-22 07:17AM
Dec-28-22 08:00AM
Nov-23-22 08:00AM
Nov-17-22 08:00AM
Nov-09-22 10:47AM
(American City Business Journals)
09:15AM
08:00AM
Nov-02-22 04:05PM
08:00AM
Oct-26-22 08:00AM
Oct-04-22 07:00AM
Sep-28-22 06:44AM
Sep-01-22 08:00AM
Aug-24-22 07:00AM
Aug-15-22 04:00PM
(American City Business Journals)
-5.18%
Aug-11-22 09:15AM
08:00AM
Aug-10-22 10:50AM
(American City Business Journals) +7.69%
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jonasson Zachariah CFO / CBO Jun 13 '24 Option Exercise 3.39 28,700 97,293 404,610 Jun 14 04:40 PM Jonasson Zachariah CFO / CBO Jun 13 '24 Sale 4.98 19,859 98,892 384,751 Jun 14 04:40 PM Phoenix Venture Partners II LP 10% Owner May 22 '24 Sale 4.40 3,100,000 13,640,000 11,279,522 May 28 01:56 PM Redmile Group, LLC Director Mar 01 '24 Buy 4.50 222,222 999,999 8,253,316 Mar 05 09:30 PM
Index RUT
P/E -
EPS (ttm) -1.71
Insider Own 16.69%
Shs Outstand 98.63M
Perf Week -3.73%
Market Cap 440.72M
Forward P/E -
EPS next Y -1.65
Insider Trans -0.00%
Shs Float 94.87M
Perf Month -1.02%
Income -175.72M
PEG -
EPS next Q -0.42
Inst Own 93.16%
Short Float 15.99%
Perf Quarter 2.93%
Sales 12.32M
P/S 35.77
EPS this Y -0.05%
Inst Trans -2.38%
Short Ratio 8.53
Perf Half Y -47.91%
Book/sh 3.49
P/B 1.11
EPS next Y -0.81%
ROA -31.56%
Short Interest 15.17M
Perf Year 72.00%
Cash/sh 2.68
P/C 1.45
EPS next 5Y -
ROE -42.10%
52W Range 1.63 - 8.83
Perf YTD 3.48%
Dividend Est. -
P/FCF -
EPS past 5Y -6.65%
ROI -35.80%
52W High -56.17%
Beta 1.84
Dividend TTM -
Quick Ratio 9.18
Sales past 5Y 87.14%
Gross Margin -55.61%
52W Low 137.42%
ATR (14) 0.30
Dividend Ex-Date -
Current Ratio 9.18
EPS Y/Y TTM 21.30%
Oper. Margin -1587.28%
RSI (14) 51.54
Volatility 7.07% 7.58%
Employees 181
Debt/Eq 0.25
Sales Y/Y TTM -89.67%
Profit Margin -1426.67%
Recom 2.65
Target Price 6.62
Option/Short Yes / Yes
LT Debt/Eq 0.24
EPS Q/Q 38.99%
Payout -
Rel Volume 1.42
Prev Close 4.00
Sales Surprise 410.52%
EPS Surprise 28.80%
Sales Q/Q 625.83%
Earnings Aug 13 AMC
Avg Volume 1.78M
Price 3.87
SMA20 3.95%
SMA50 -4.15%
SMA200 -17.13%
Trades
Volume 2,529,331
Change -3.25%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-17-24 Upgrade
Piper Sandler
Neutral → Overweight
$4 → $6
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade
H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade
Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade
Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade
Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade
Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade
Cowen
Outperform → Market Perform
Jan-06-23 Downgrade
BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade
BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade
Guggenheim
Buy → Neutral
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Dec-15-22 Initiated
Goldman
Sell
$10
Nov-04-22 Resumed
Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated
Canaccord Genuity
Buy
$42
Aug-18-22 Resumed
Wells Fargo
Overweight
$90
Jul-28-22 Initiated
Needham
Hold
Jul-11-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated
Robert W. Baird
Neutral
$28
Feb-11-22 Resumed
BMO Capital Markets
Market Perform
$50
Show Previous Ratings
Sep-12-24 04:01PM
11:30AM
Aug-16-24 12:00PM
Aug-13-24 05:25PM
04:25PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Aug-02-24 04:01PM
(GlobeNewswire) -5.12%
-9.50%
Jul-31-24 08:00AM
Jul-21-24 05:37AM
Jul-02-24 04:01PM
Jun-04-24 04:01PM
May-29-24 04:01PM
May-13-24 10:48AM
May-10-24 02:50PM
10:36AM
08:22AM
Loading…
08:22AM
May-09-24 08:58PM
05:25PM
04:21PM
(Associated Press Finance)
04:01PM
08:30AM
May-06-24 08:00AM
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
04:01PM
Loading…
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
(GlobeNewswire) +11.67%
+11.19%
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
(Thomson Reuters StreetEvents)
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Mar-27-23 09:00AM
Mar-03-23 04:01PM
Mar-02-23 09:18PM
05:30AM
Mar-01-23 09:59AM
Feb-28-23 05:15PM
04:01PM
Feb-27-23 09:31AM
Feb-13-23 08:00AM
Feb-06-23 09:55AM
Feb-02-23 09:46AM
Jan-30-23 07:33AM
Jan-28-23 01:30PM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Xu Yuan Director Aug 06 '24 Sale 4.23 633 2,678 8,669 Aug 07 04:01 PM Xu Yuan Director Aug 06 '24 Proposed Sale 4.23 633 2,678 Aug 06 10:34 AM Dulac Edward J III Chief Financial Officer Mar 04 '24 Sale 7.77 2,447 19,013 101,479 Mar 05 04:24 PM Dulac Edward J III Chief Financial Officer Jan 29 '24 Sale 5.00 1,849 9,245 103,926 Jan 30 04:01 PM TAHL CINDY General Counsel and Secretary Jan 09 '24 Sale 4.37 10,874 47,519 142,361 Jan 10 04:30 PM Valamehr Bahram Chief R&D Officer Jan 09 '24 Sale 4.38 11,271 49,367 158,069 Jan 10 04:30 PM Wolchko J Scott President and CEO Jan 09 '24 Sale 4.37 14,391 62,889 371,248 Jan 10 04:29 PM Dulac Edward J III Chief Financial Officer Jan 09 '24 Sale 4.37 7,028 30,712 105,775 Jan 10 04:29 PM Dulac Edward J III Chief Financial Officer Jan 02 '24 Sale 3.66 5,182 18,966 112,803 Jan 03 04:03 PM Redmile Group, LLC Director Dec 26 '23 Buy 3.72 44,630 166,024 13,180,388 Dec 28 09:30 PM Dulac Edward J III Chief Financial Officer Dec 18 '23 Sale 3.50 1,585 5,548 117,985 Dec 19 04:01 PM TAHL CINDY General Counsel and Secretary Nov 09 '23 Sale 2.40 24,363 58,471 153,235 Nov 13 04:01 PM
Index -
P/E -
EPS (ttm) -0.47
Insider Own 1.51%
Shs Outstand 49.43M
Perf Week 0.43%
Market Cap 115.67M
Forward P/E -
EPS next Y -0.51
Insider Trans -37.85%
Shs Float 48.68M
Perf Month 3.08%
Income -23.85M
PEG -
EPS next Q -0.14
Inst Own 81.78%
Short Float 2.71%
Perf Quarter 191.23%
Sales 51.58M
P/S 2.24
EPS this Y -20.45%
Inst Trans 0.67%
Short Ratio 1.56
Perf Half Y -44.94%
Book/sh 0.21
P/B 10.97
EPS next Y 3.77%
ROA -48.91%
Short Interest 1.32M
Perf Year -55.43%
Cash/sh 0.57
P/C 4.10
EPS next 5Y -
ROE -329.77%
52W Range 0.73 - 6.25
Perf YTD -60.00%
Dividend Est. -
P/FCF -
EPS past 5Y 62.58%
ROI -81.34%
52W High -62.56%
Beta 0.25
Dividend TTM -
Quick Ratio 1.66
Sales past 5Y 33.97%
Gross Margin 48.22%
52W Low 220.55%
ATR (14) 0.02
Dividend Ex-Date -
Current Ratio 1.66
EPS Y/Y TTM 14.91%
Oper. Margin -46.29%
RSI (14) 79.07
Volatility 0.43% 0.62%
Employees 1430
Debt/Eq 2.41
Sales Y/Y TTM 39.32%
Profit Margin -46.23%
Recom 3.00
Target Price 2.35
Option/Short Yes / Yes
LT Debt/Eq 1.80
EPS Q/Q -37.18%
Payout -
Rel Volume 0.20
Prev Close 2.33
Sales Surprise 0.20%
EPS Surprise -20.03%
Sales Q/Q 26.75%
Earnings Aug 12 AMC
Avg Volume 846.61K
Price 2.34
SMA20 1.15%
SMA50 10.24%
SMA200 -25.04%
Trades
Volume 167,830
Change 0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Downgrade
Lake Street
Buy → Hold
Jul-22-24 Downgrade
B. Riley Securities
Buy → Neutral
$3 → $2.35
May-14-24 Downgrade
Maxim Group
Buy → Hold
$5
May-14-24 Downgrade
Evercore ISI
Outperform → In-line
$5 → $1.50
Apr-03-24 Resumed
B. Riley Securities
Buy
$5.50
Dec-15-23 Initiated
Evercore ISI
In-line
$6
Aug-12-24 05:10PM
04:01PM
Aug-06-24 07:00AM
Jul-25-24 02:30AM
Jul-22-24 06:29AM
04:55AM
Loading…
04:55AM
Jul-19-24 03:33PM
07:00AM
Jul-15-24 11:40AM
Jun-25-24 06:33PM
Jun-20-24 11:51AM
07:00AM
Jun-04-24 07:00AM
May-29-24 07:00AM
May-14-24 12:21PM
(Thomson Reuters StreetEvents) -51.07%
09:19AM
Loading…
09:19AM
08:34AM
07:34AM
03:05AM
May-13-24 08:55PM
04:03PM
May-03-24 07:00AM
Apr-30-24 07:00AM
Apr-25-24 04:05PM
Apr-24-24 07:00AM
Apr-19-24 06:00AM
Apr-12-24 02:05AM
Apr-10-24 01:51AM
Apr-09-24 07:00AM
Apr-05-24 02:42AM
07:00AM
Loading…
Apr-04-24 07:00AM
01:56AM
Apr-02-24 08:35AM
Mar-20-24 10:13AM
Mar-19-24 06:41AM
(Thomson Reuters StreetEvents) +18.92%
Mar-18-24 08:53PM
05:31PM
04:01PM
Mar-14-24 07:04AM
Mar-12-24 07:00AM
Mar-08-24 07:00AM
Feb-27-24 07:00AM
Feb-13-24 07:00AM
Jan-22-24 04:15PM
Jan-16-24 07:00AM
Jan-05-24 08:00AM
Dec-22-23 07:00AM
Dec-13-23 10:29AM
Nov-21-23 07:00AM
Nov-16-23 08:51AM
12:15AM
Nov-15-23 04:02PM
Nov-10-23 09:55AM
08:50AM
Nov-07-23 09:55AM
Nov-06-23 05:10PM
04:02PM
Oct-30-23 07:00AM
Oct-20-23 08:02AM
Oct-12-23 07:59AM
Oct-09-23 08:50AM
Oct-05-23 07:15AM
07:00AM
Sep-27-23 07:00AM
Sep-25-23 07:54AM
Sep-22-23 06:39AM
Sep-21-23 08:50AM
07:00AM
Sep-20-23 07:22AM
Sep-12-23 09:40AM
Sep-06-23 07:00AM
Sep-05-23 08:50AM
Sep-04-23 09:55AM
Aug-24-23 09:40AM
07:00AM
Aug-18-23 07:00AM
Aug-16-23 09:55AM
08:50AM
Aug-09-23 09:25AM
Aug-08-23 03:27PM
Aug-07-23 05:50PM
04:02PM
Jul-28-23 07:00AM
Jul-12-23 08:29AM
Jul-10-23 08:42AM
Jul-07-23 11:04AM
Jun-29-23 08:50AM
Jun-16-23 09:40AM
Jun-14-23 07:05AM
Jun-12-23 07:00AM
May-31-23 09:40AM
May-19-23 08:24AM
May-12-23 08:15AM
07:00AM
May-08-23 07:00AM
May-05-23 01:34PM
Apr-28-23 06:47PM
06:47PM
Apr-20-23 06:31AM
06:30AM
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chatterjee Saurav CHIEF TECHNOLOGY OFFICER May 15 '24 Sale 1.19 1,767 2,103 2,921 May 17 09:00 PM Shakil Ian CHIEF STRATEGY OFFICER May 15 '24 Sale 1.19 1,387 1,651 5,363 May 17 09:00 PM Ginocchio Paul CHIEF FINANCIAL OFFICER May 15 '24 Sale 1.19 2,354 2,801 131,896 May 17 09:00 PM Hawkins Jonathan CHIEF REVENUE OFFICER May 15 '24 Sale 1.19 1,767 2,103 2,921 May 17 09:00 PM Krakaris Emmanuel PRESIDENT, CEO, AND SECRETARY May 15 '24 Sale 1.19 3,528 4,198 58,898 May 17 09:00 PM Breber Sandra CHIEF OPERATING OFFICER May 15 '24 Sale 1.19 2,354 2,801 16,396 May 17 09:00 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 15 '24 Option Exercise 0.86 500 430 3,500 Apr 16 09:07 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 15 '24 Sale 3.80 500 1,900 3,000 Apr 16 09:07 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 12 '24 Option Exercise 0.86 19,544 16,808 22,544 Apr 15 09:15 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 12 '24 Sale 3.82 19,544 74,590 3,000 Apr 15 09:15 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 10 '24 Option Exercise 0.86 36,467 31,362 39,467 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 09 '24 Option Exercise 0.76 31,542 23,968 34,542 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 11 '24 Option Exercise 0.86 24,778 21,309 27,778 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 10 '24 Sale 3.87 36,467 141,288 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 09 '24 Sale 4.14 31,542 130,521 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 11 '24 Sale 3.93 24,778 97,477 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 08 '24 Option Exercise 0.64 28,563 18,280 40,780 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 05 '24 Sale 4.03 51,387 207,233 12,217 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 08 '24 Sale 3.97 37,780 149,968 3,000 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 04 '24 Sale 4.15 64,055 265,854 31,610 Apr 04 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 03 '24 Sale 4.11 45,906 188,600 95,665 Apr 04 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 01 '24 Option Exercise 0.64 51,346 32,861 239,012 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 01 '24 Sale 3.91 58,978 230,384 180,034 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 02 '24 Sale 3.89 38,463 149,725 141,571 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Mar 28 '24 Sale 4.06 31,994 129,851 187,666 Apr 01 08:28 PM Ginocchio Paul CHIEF FINANCIAL OFFICER Nov 22 '23 Buy 4.85 10,000 48,500 128,000 Nov 27 07:00 AM Redmile Group, LLC Director Nov 20 '23 Buy 4.00 750,000 3,000,000 16,404,017 Nov 22 04:15 PM Redmile Group, LLC Director Nov 20 '23 Buy 4.00 750,000 3,000,000 9,446,146 Nov 22 04:15 PM
Index RUT
P/E -
EPS (ttm) -3.68
Insider Own 64.79%
Shs Outstand 33.18M
Perf Week 31.38%
Market Cap 958.61M
Forward P/E -
EPS next Y -2.86
Insider Trans 0.94%
Shs Float 20.89M
Perf Month 48.80%
Income -220.40M
PEG -
EPS next Q -0.79
Inst Own 37.39%
Short Float 26.51%
Perf Quarter 121.37%
Sales 2.91M
P/S 329.42
EPS this Y 33.78%
Inst Trans -0.70%
Short Ratio 17.77
Perf Half Y 57.97%
Book/sh 2.07
P/B 7.82
EPS next Y 8.23%
ROA -53.94%
Short Interest 5.54M
Perf Year 131.85%
Cash/sh 4.33
P/C 3.73
EPS next 5Y -
ROE -115.71%
52W Range 3.81 - 22.50
Perf YTD 94.46%
Dividend Est. -
P/FCF -
EPS past 5Y -44.65%
ROI -141.47%
52W High -28.18%
Beta 0.17
Dividend TTM -
Quick Ratio 7.06
Sales past 5Y 19.85%
Gross Margin -205.46%
52W Low 324.15%
ATR (14) 1.79
Dividend Ex-Date -
Current Ratio 7.06
EPS Y/Y TTM 30.22%
Oper. Margin -8137.82%
RSI (14) 67.91
Volatility 24.70% 13.34%
Employees 224
Debt/Eq 0.32
Sales Y/Y TTM 74.00%
Profit Margin -7571.35%
Recom 1.67
Target Price 23.88
Option/Short Yes / Yes
LT Debt/Eq 0.27
EPS Q/Q 44.48%
Payout -
Rel Volume 1.92
Prev Close 17.23
Sales Surprise -97.69%
EPS Surprise -1841.03%
Sales Q/Q 179.91%
Earnings Aug 14 BMO
Avg Volume 311.52K
Price 16.16
SMA20 36.69%
SMA50 49.84%
SMA200 64.04%
Trades
Volume 597,969
Change -6.21%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade
BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade
H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed
Jefferies
Buy
$61 → $55
Oct-17-22 Initiated
JP Morgan
Neutral
$27
Aug-29-22 Initiated
BofA Securities
Buy
$34
Dec-13-21 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade
Wedbush
Neutral → Outperform
Aug-26-21 Initiated
Morgan Stanley
Overweight
$100
Jan-29-21 Initiated
RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated
H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade
Wedbush
Outperform → Neutral
Jul-17-20 Initiated
Robert W. Baird
Outperform
$90
Jul-01-20 Initiated
H.C. Wainwright
Buy
$88
May-28-20 Initiated
SunTrust
Buy
$86
Apr-22-20 Initiated
Wedbush
Outperform
$73
Oct-14-19 Initiated
Stifel
Buy
$32
Oct-14-19 Initiated
Piper Jaffray
Overweight
$26
Oct-14-19 Initiated
Jefferies
Buy
$25
Oct-14-19 Initiated
Guggenheim
Buy
$30
Show Previous Ratings
Sep-18-24 09:33AM
Sep-10-24 04:05PM
Aug-22-24 12:00PM
Aug-14-24 08:00AM
07:00AM
09:35AM
Loading…
Jul-12-24 09:35AM
May-29-24 07:00AM
May-10-24 02:38PM
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM
04:10PM
May-07-24 07:00AM
May-03-24 10:00AM
Apr-30-24 12:00PM
08:30AM
Loading…
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
02:46AM
Loading…
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
(GlobeNewswire) -7.06%
-10.66%
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
(GlobeNewswire) +5.92%
-22.13%
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
(GlobeNewswire) +8.33%
-8.47%
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Weber Steven PRINCIPAL ACCOUNTING OFFICER Sep 13 '24 Sale 11.54 469 5,412 25,543 Sep 17 08:58 PM Takimoto Chris H CHIEF MEDICAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 154,331 Sep 17 08:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 122,694 Sep 17 08:54 PM Schwarzer Fred CEO AND PRESIDENT Sep 13 '24 Sale 11.54 3,946 45,532 250,124 Sep 17 08:52 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 242,948 Sep 17 08:50 PM Harler Mary Beth Head, Research & Autoimmunity Sep 13 '24 Sale 11.54 1,487 17,158 163,740 Sep 17 08:44 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Sep 13 '24 Sale 11.54 925 10,673 79,104 Sep 17 08:42 PM Hambleton Julie Director Jul 25 '24 Option Exercise 1.39 15,132 21,033 17,132 Jul 29 05:45 PM Hambleton Julie Director Jul 25 '24 Sale 14.00 15,132 211,848 2,000 Jul 29 05:45 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Jun 14 '24 Sale 7.58 495 3,750 26,012 Jun 18 07:45 PM Takimoto Chris H CHIEF MEDICAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 95,818 Jun 18 07:44 PM Tahir Misbah CHIEF FINANCIAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 88,848 Jun 18 07:43 PM Schwarzer Fred CEO AND PRESIDENT Jun 14 '24 Sale 7.58 4,164 31,544 254,070 Jun 18 07:42 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Jun 14 '24 Sale 7.58 1,106 8,378 197,769 Jun 18 07:41 PM Harler Mary Beth Head, Research & Autoimmunity Jun 14 '24 Sale 7.58 1,570 11,893 85,227 Jun 18 07:40 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Jun 14 '24 Sale 7.58 977 7,401 60,029 Jun 18 07:38 PM BAKER BROS. ADVISORS LP Director Mar 26 '24 Buy 8.26 270,000 2,230,767 3,638,533 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 28 '24 Buy 9.62 97,473 937,632 3,753,480 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 27 '24 Buy 9.24 27,844 257,170 3,664,073 Mar 28 07:04 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 13 '24 Sale 9.88 529 5,224 26,971 Mar 15 07:57 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '24 Sale 10.17 464 4,719 26,507 Mar 15 07:57 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.88 2,889 28,529 96,923 Mar 15 07:55 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 14 '24 Sale 10.17 2,535 25,782 94,388 Mar 15 07:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 13 '24 Sale 9.88 2,897 28,608 92,961 Mar 15 07:53 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '24 Sale 10.17 2,543 25,864 90,418 Mar 15 07:53 PM Schwarzer Fred CEO AND PRESIDENT Mar 13 '24 Sale 9.88 4,765 47,055 220,833 Mar 15 07:51 PM Schwarzer Fred CEO AND PRESIDENT Mar 14 '24 Sale 10.17 4,182 42,533 216,651 Mar 15 07:51 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 13 '24 Sale 9.88 2,101 20,748 173,700 Mar 15 07:49 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 14 '24 Sale 10.17 1,844 18,754 171,856 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 13 '24 Sale 9.88 1,798 17,756 62,584 Mar 15 07:48 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '24 Sale 10.17 1,578 16,049 61,006 Mar 15 07:48 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 01 '24 Option Exercise 0.93 3,026 2,814 4,039 Mar 05 07:34 PM Schwarzer Fred CEO and President Dec 13 '23 Sale 5.78 17,576 101,558 102,848 Dec 15 07:20 PM Keyt Bruce Chief Scientific Officer Dec 13 '23 Sale 5.78 7,574 43,764 129,551 Dec 15 07:19 PM Decker Lisa Lynn Chief Business Officer Dec 13 '23 Sale 5.78 4,369 25,245 35,632 Dec 15 07:18 PM BAKER BROS. ADVISORS LP Director Dec 15 '23 Buy 6.55 288,007 1,887,531 3,390,323 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 6.50 157,370 1,023,157 3,123,585 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 5.96 87,316 520,776 2,977,836 Dec 15 05:32 PM Takimoto Chris H Chief Medical Officer Nov 29 '23 Sale 6.21 1,180 7,331 53,562 Dec 01 07:03 PM Gauthier George Chief Commercial Officer Nov 29 '23 Sale 6.21 1,180 7,331 39,642 Dec 01 07:02 PM Decker Lisa Lynn Chief Business Officer Nov 29 '23 Sale 6.21 1,180 7,331 40,001 Dec 01 07:01 PM Tahir Misbah Chief Financial Officer Nov 27 '23 Sale 5.06 1,337 6,764 49,608 Nov 29 08:49 PM Schwarzer Fred CEO and President Nov 27 '23 Sale 5.06 1,337 6,764 120,424 Nov 29 08:48 PM Keyt Bruce Chief Scientific Officer Nov 27 '23 Sale 5.06 933 4,720 137,125 Nov 29 08:47 PM Gauthier George Chief Commercial Officer Oct 02 '23 Sale 7.95 935 7,430 39,082 Oct 03 07:55 PM
Index RUT
P/E -
EPS (ttm) -1.52
Insider Own 2.72%
Shs Outstand 70.12M
Perf Week 4.39%
Market Cap 937.51M
Forward P/E -
EPS next Y -1.16
Insider Trans 0.00%
Shs Float 69.67M
Perf Month 17.93%
Income -112.51M
PEG -
EPS next Q -0.40
Inst Own 96.31%
Short Float 6.04%
Perf Quarter 55.65%
Sales 62.71M
P/S 14.95
EPS this Y 35.59%
Inst Trans -0.51%
Short Ratio 6.02
Perf Half Y 22.91%
Book/sh 5.69
P/B 2.30
EPS next Y -4.69%
ROA -20.13%
Short Interest 4.21M
Perf Year 97.14%
Cash/sh 4.61
P/C 2.84
EPS next 5Y 11.00%
ROE -26.32%
52W Range 6.01 - 13.14
Perf YTD 25.99%
Dividend Est. -
P/FCF -
EPS past 5Y -6.52%
ROI -26.57%
52W High -0.38%
Beta 1.19
Dividend TTM -
Quick Ratio 7.01
Sales past 5Y 264.10%
Gross Margin 76.51%
52W Low 117.62%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 7.01
EPS Y/Y TTM -154.13%
Oper. Margin -191.47%
RSI (14) 77.12
Volatility 3.75% 3.71%
Employees 277
Debt/Eq 0.05
Sales Y/Y TTM -85.99%
Profit Margin -179.42%
Recom 1.86
Target Price 14.00
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 35.12%
Payout -
Rel Volume 1.06
Prev Close 13.05
Sales Surprise 61.22%
EPS Surprise -17.37%
Sales Q/Q 174.82%
Earnings Aug 01 AMC
Avg Volume 699.36K
Price 13.09
SMA20 10.07%
SMA50 19.70%
SMA200 29.09%
Trades
Volume 742,271
Change 0.31%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-23 Resumed
Wells Fargo
Overweight
$12
Jan-04-23 Reiterated
H.C. Wainwright
Neutral
$10 → $8
Dec-20-22 Upgrade
Jefferies
Hold → Buy
$7.70 → $11
Nov-01-22 Downgrade
H.C. Wainwright
Buy → Neutral
$40 → $8
Oct-21-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$8
Oct-04-22 Resumed
Wells Fargo
Overweight
$45 → $9
May-05-22 Upgrade
Guggenheim
Neutral → Buy
$14
Mar-15-22 Initiated
Evercore ISI
Outperform
$15
Dec-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
Nov-17-21 Resumed
Guggenheim
Neutral
Oct-07-21 Initiated
Jefferies
Hold
$32
Mar-31-21 Initiated
Credit Suisse
Outperform
$55
Feb-25-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$41
Feb-08-21 Resumed
H.C. Wainwright
Buy
$57
Jan-25-21 Downgrade
Citigroup
Buy → Neutral
$50 → $53
Sep-29-20 Resumed
JP Morgan
Neutral
$48
Aug-06-20 Initiated
SVB Leerink
Outperform
$45
Jan-10-20 Initiated
Wolfe Research
Outperform
$61
Dec-09-19 Initiated
JP Morgan
Neutral
Nov-25-19 Initiated
H.C. Wainwright
Buy
$65
Show Previous Ratings
Sep-19-24 12:08PM
Sep-18-24 06:00AM
Sep-03-24 04:30PM
Aug-22-24 06:30AM
Aug-01-24 04:10PM
04:05PM
Loading…
04:05PM
Jul-30-24 06:30AM
Jul-25-24 04:30PM
Jul-22-24 06:00AM
Jul-11-24 06:30AM
Jun-17-24 06:00AM
Jun-10-24 06:00AM
May-28-24 06:30AM
May-19-24 09:00PM
May-16-24 04:20PM
04:05PM
Loading…
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 09:35AM
Apr-08-24 06:00AM
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
(FierceBiotech.com) -6.46%
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
06:00AM
Loading…
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Galbraith Kenneth Chair & CEO Jan 05 '24 Option Exercise 0.00 47,666 0 47,666 Jan 08 06:23 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Sale 10.65 18,198 193,849 29,468 Jan 08 06:23 PM Galbraith Kenneth Chair & CEO Jan 08 '24 Sale 11.22 5,706 63,996 23,762 Jan 08 06:23 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Option Exercise 0.00 10,500 0 12,497 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Sale 10.65 4,563 48,606 7,934 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Jan 08 '24 Sale 11.22 1,431 16,050 6,503 Jan 08 06:14 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Option Exercise 0.00 17,166 0 17,166 Jan 08 06:01 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Sale 10.65 7,460 79,465 9,706 Jan 08 06:01 PM Moore Paul Andrew Chief Scientific Officer Jan 08 '24 Sale 11.22 2,339 26,233 7,367 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Option Exercise 0.00 1,550 0 2,883 Dec 11 08:00 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Sale 9.13 886 8,089 1,997 Dec 11 08:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite